Background: Hereditary susceptibility to familial paraganglioma syndromes is mainly due to mutations in one of six genes, including three of the four genes encoding the subunits of the mitochondrial succinate dehydrogenase complex II. Although prevalence, penetrance and clinical characteristics of patients carrying point mutations affecting the genes encoding succinate dehydrogenase have been well studied, little is known regarding these clinical features in patients with gross deletions. Recently, we found two unrelated Spanish families carrying the previously reported SDHB exon 1 deletion, and suggested that this chromosomal region could be a hotspot deletion area.
Methods: We present the molecular characterisation of this apparently prevalent mutation in three new families, and discuss whether this recurrent mutation is due either to the presence of a founder effect or to a hotspot.
Results: The breakpoint analysis showed that all Iberian Peninsular families described harbour the same exon 1 deletion, and that a different breakpoint junction segregates in an affected French pedigree.
Conclusions: After haplotyping the SDHB region, we concluded that the deletion detected in Iberian Peninsular people is probably due to a founder effect. Regarding the clinical characteristics of patients with this alteration, it seems that the presence of gross deletions rather than point mutations is more likely related to abdominal presentations and younger age at onset. Moreover, we found for the first time a patient with neuroblastoma and a germline SDHB deletion, but it seems that this paediatric neoplasia in a pheochromocytoma family is not a key component of this disease.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding: This work was supported in part by the Fondo de Investigaciones Sanitarias, projects PI061477 and PI042154, project ISCIII CIBER-ER from the Spanish Ministry of Health, the Deutsche Krebshilfe (70-3313-Ne 1 to HPHN), the Deutsche Forschungsgemeinschaft (NE 571/5-3 to HPHN), and the European Union (LSHC-CT-2005-518200 to HPHN). Alberto Cascon and Cristina Rodríguez-Antona have FIS and ‘Ramon y Cajal’ contracts, respectively, from the Spanish government. Charis Eng is a Doris Duke Distinguished Clinical Scientist.
Competing interests: None declared.
Patient consent: Informed consent was obtained for publication of the patients’ details in this report.